References
- Lewin J, Ranchod M, Dorfman R F, et al. Lymphomas of the gastrointestinal tract. Cancer 1978; 42: 693–707
- Collins J, Katon R, Harry-Golder B, et al. Burkitt lymphoma presenting with gastroduodenal involvement. Gastroenterology 1983; 85: 425–429
- Wotherspoon A C, Ortiz-Hidalgo C, Falzon M R, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338: 1175
- Grewal S S, Hunt J P, O'connor S C, et al. Helicobacter pylori associated gastric Burkitt lymphoma. Pediatr Blood Cancer 2008; 50: 888–890
- Park Y H, Kim W S, Kang H J, et al. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol 2006; 85: 285–290
- Du M Q. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol 2007; 47: 31–42
- D'Elios M M, Amedei A, Manghetti M, et al. Impaired T-Cell regulation of B-cell growth in Helicobacter pylori – related gastric low-grade MALT lymphoma. Gastroenterology 1999; 117: 1105–1112
- Moschovi M, Menegas D, Stefanaki K, et al. Primary gastric burkitt lymphoma in childhood: associated with Helicobacter pylori?. Med Pediatr Oncol 2003; 41: 444–447
- Shannon C, Vickers C, Field A, et al. Burkitt's lymphoma associated with Helicobacter pylori. J Gastroenterol Hepatol 2000; 15: 99–103
- Cather J C, Cather J C, Menter A, et al. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3: 361–370
- Leonardi C L, Toth D, Cather J C, et al. A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006; 213: 204–214
- Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 2006; 5: 197–209
- Bommakanti S, Patil A, Eshoa C, et al. Case reports: efalizumab-associated lymphoproliferative disease. J Drugs Dermatol 2007; 6: 646–648
- Berthelot C, Cather J, Jones D, et al. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. Clin Lymphoma Myeloma 2006; 6: 329–332
- Efalizumab (marketed as Raptiva) Information http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm133337.htm, accessed June 25th 2009.